FDA's 2026 peptide compounding review may change how certain licensed compounding pharmacies can work with specific peptide bulk drug substances, but it does not make peptide businesses automatically eligible for payment processing. It also does not turn peptides into supplements, over-the-counter products, or low-risk wellness products.
For merchant account approval, the practical question is narrower and more commercial: can the business prove that its website, product positioning, documentation, fulfillment model, and chargeback history match the way the business is asking the bank to underwrite it?
That is where many peptide businesses get into trouble. A clinic may read an FDA headline and assume payment risk has gone down. A bank or card-network-facing underwriter looks at something different. They review product claims, prescription workflows, COAs, supplier documentation, refund practices, chargebacks, MCC alignment, previous processor history, and whether the merchant is describing the business honestly.
The FDA discussion matters. It should be taken seriously. But it is only one piece of the underwriting file.
What FDA Is Reviewing in 2026
FDA has scheduled a July 23 to 24, 2026 meeting of the Pharmacy Compounding Advisory Committee to discuss several bulk drug substances being considered for inclusion on the Section 503A Bulks List.[1]
The July meeting agenda names BPC-157-related substances, KPV-related substances, TB-500-related substances, MOTs-C-related substances, Emideltide, Semax, and Epitalon.[1] Regulatory Affairs Professionals Society also reported that FDA is considering whether a dozen peptide drugs should be eligible for compounding by licensed facilities, with seven peptides scheduled for July review and five additional peptides expected to be discussed before the end of February 2027.[4]
FDA’s category 2 compounding-risk page identifies potential significant safety risks for several nominated peptides, including immunogenicity, peptide-related impurities, limited safety information, and serious adverse-event concerns.[5] That context matters because underwriters do not treat the topic as a simple green light. They see a category that is active, commercially attractive, closely watched, and still documentation-heavy.
| FDA item | What it means | What it does not mean |
|---|---|---|
| Advisory committee meeting | FDA is gathering expert input on specific bulk drug substances. | It is not the same as final approval for every peptide business model. |
| 503A Bulks List review | Certain substances may be evaluated for use by eligible 503A compounders under specific conditions. | It does not make peptides dietary supplements or OTC wellness products. |
| Category discussion | FDA's interim compounding categories affect how nominated bulk substances are evaluated. | It does not remove card-brand underwriting, advertising review, or merchant due diligence. |
| Public attention | More patients, clinics, and merchants are watching the space. | More attention can also mean more scrutiny from banks, platforms, and card networks. |
Category 1 Does Not Mean Low Risk
A common mistake is treating Category 1 as a casual approval label.
FDA describes Category 1 substances as nominated bulk drug substances that may be eligible for inclusion on the 503A Bulks List, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on another list.[2] FDA says it does not intend to take action against a compounder for using Category 1 substances when the conditions in the guidance are met.[2]
That is not the same as saying every business selling or marketing peptides is safe for payment processing. FDA describes Category 2 substances differently. These are substances that may be eligible for inclusion on the 503A Bulks List, but FDA has identified significant safety risks relating to their use in compounding pending further evaluation.[2]
For a merchant account, the underwriting point is simple. If a business cannot explain whether it is a licensed clinic, a 503A pharmacy relationship, a 503B outsourcing facility relationship, a telehealth model, a med spa, or a research-use-only seller, the file becomes harder to approve. Ambiguity is not a risk strategy. It is usually the reason an underwriter asks for more documents or declines the account.
FDA movement may change the regulatory conversation, but it does not replace the underwriting file. Banks still need to see documentation, truthful positioning, and a business model they can monitor.
Why Banks Still Care After an FDA Headline
Payment processors do not underwrite peptide merchants only by checking whether a product name appeared in an FDA meeting notice.
Acquirers and processors have to protect the payment system from illegal transactions, excessive disputes, transaction laundering, deceptive marketing, brand damage, and rule violations. Visa states that before a merchant can accept Visa payments, the acquirer must conduct compliance checks to meet Visa standards.[8] Visa also explains that some legal merchant categories carry elevated risk of illegal activity and require enhanced safeguards from the acquirers that support them.[8]
That is the commercial reality behind peptide underwriting. The payment question is not only, "Is this product being discussed by FDA?" The question is, "Can this merchant be boarded truthfully, monitored effectively, and defended if the bank, card brand, or compliance partner reviews the file?"
What Underwriters Review Before Approving a Peptide Merchant Account
A strong application does not ask the underwriter to guess. It makes the business model clear, removes unsupported claims, and gives the bank a clean file.
| Underwriting area | What a stronger file shows | Why it matters |
|---|---|---|
| Business model | The merchant clearly explains whether it is a clinic, telehealth provider, med spa, compounding-adjacent model, pharmacy relationship, or RUO seller. | Misclassification creates risk for MCC assignment, card-brand registration, and monitoring. |
| Website claims | The site avoids disease treatment claims, cure claims, weight-loss promises, dosing guidance, and unsupported before-and-after language. | FTC guidance says health-related advertising must be truthful, not misleading, and adequately substantiated.[6] |
| Product documentation | Current COAs are available, product pages match the intended use, and supplier documents support the model. | FDA says bulk drug substances under 503A must be accompanied by a valid certificate of analysis and be manufactured by a registered establishment.[2] |
| Processing history | Bank statements and prior processor statements show volume, refunds, disputes, and chargeback patterns. | Underwriters need to know whether the account can be monitored and priced correctly. |
| Fulfillment and refunds | Shipping, customer service, refund, and cancellation policies are clear. | Confusion in fulfillment and refunds often turns into disputes. |
| Prior terminations | The merchant explains what happened and what changed. | A prior termination does not automatically end the conversation, but silence makes the file weaker. |
The Website Is Part of the Underwriting File
Many peptide operators think underwriting starts when they submit bank statements. In practice, underwriting starts when the reviewer opens the website.
If the website says "research only" on one page but promises fat loss, injury recovery, anti-aging, or disease treatment on another page, the file is inconsistent. If product pages include dosing instructions while the business says it does not sell for human use, the file is inconsistent. If testimonials describe patient outcomes for RUO products, the file is inconsistent.
FTC's Health Products Compliance Guidance states that advertising for health-related products must be truthful, not misleading, and supported by adequate substantiation.[6] FTC also states that health benefit and safety claims generally require competent and reliable scientific evidence.[6] That matters for payment approval because processors are not just reviewing products. They are reviewing how the merchant creates consumer demand.
Special Issue: GLP-1 and Copycat Compounding Language
GLP-1 demand has made peptide processing more sensitive.
FDA's April 1, 2026 update reminded compounders that certain conditions must be met for compounded drugs to qualify for exemptions under Sections 503A and 503B.[3] Under 503A, FDA highlighted patient-specific prescription requirements and limits on compounding drugs that are essentially copies of commercially available drug products.[3]
The lesson for clinics is not to overstate regulatory certainty. If the business offers compounded products, the application should explain the clinical, pharmacy, prescription, and fulfillment model clearly. If the business sells RUO products, it should not borrow clinic language, patient language, or therapeutic language to drive conversions.
LegitScript, Card Brands, and What DIVIOR Does Differently
LegitScript states that card networks such as Visa and Mastercard recognize LegitScript Certification as part of high-risk merchant registration and compliance monitoring.[10]
That does not mean every peptide merchant must have LegitScript certification before speaking with DIVIOR. DIVIOR does not require LegitScript certification for onboarding. What DIVIOR does require is a defensible application file. That means clear business identity, clean website language, current documentation, accurate product positioning, and underwriting that matches the actual risk profile.
For some merchants, that file may involve pharmacy or telehealth documentation. For others, it may involve RUO positioning, COAs, legal review, product controls, and evidence that the business is not marketing products for human use. The right structure depends on the merchant. It should not be guessed at from a headline.
The Pre-Application Cleanup Checklist
Before applying for a peptide merchant account, a clinic or RUO peptide merchant should fix the parts of the file that can create avoidable delays.
| Step | What to review | Practical standard |
|---|---|---|
| 1 | Product pages | Remove unsupported disease, cure, fat-loss, bodybuilding, anti-aging, or recovery promises unless the business has a lawful and documented basis to make them. |
| 2 | RUO language | If products are research-use-only, make that positioning consistent across product pages, FAQs, checkout, policies, and marketing. |
| 3 | COAs | Match COAs to active SKUs and make sure they are current, legible, third-party, and easy to retrieve. |
| 4 | Policies | Publish clear shipping, refund, privacy, terms, and customer-service policies. |
| 5 | Processing history | Gather recent processing statements, bank statements, chargeback reports, refund history, and any termination notices. |
| 6 | Business documentation | Prepare entity documents, ownership information, licenses where applicable, supplier documentation, and legal reviews where available. |
| 7 | Claims governance | Remove testimonials and social content that imply patient outcomes if the business cannot support them. |
| 8 | Payment truthfulness | Do not apply under a softer category that does not match the actual business. The underwritten model must match the real model. |
The last point is often the most important. A merchant account built on a mismatch is not stable. It may process for a short period, but the same mismatch can trigger reserves, termination, funding holds, or difficulty moving to another provider later.
Where DIVIOR Fits
FDA movement may help legitimate operators by creating a more documented public record around specific substances, compounding use cases, and safety considerations.
For payment underwriting, better documentation can help. A merchant that understands FDA categories, avoids exaggerated claims, keeps COAs organized, and distinguishes clinical use from RUO positioning is easier to evaluate than a merchant that treats all peptides as one generic wellness category.
DIVIOR works with health and wellness operators that standard processors often decline, including peptide clinics, telehealth platforms, med spas, compounding-adjacent operators, supplement brands, and research-use-only peptide merchants. The difference is not that DIVIOR ignores risk. The difference is that DIVIOR is built to review the risk directly.
That means human underwriting, USA-based support, direct BIN access, accurate MCC alignment, and payment infrastructure built for regulated health and wellness categories. For qualified peptide merchants, DIVIOR can support Visa, Mastercard, and Discover processing, with approval decisions based on the merchant's actual file.